Cell Therapies in Sarcomas: Lete-cel in Synovial Sarcoma & MRCLs скачать в хорошем качестве

Cell Therapies in Sarcomas: Lete-cel in Synovial Sarcoma & MRCLs

In this episode of OncoDaily, Dr. Sandra D'Angelo, a renowned sarcoma expert from Memorial Sloan Kettering Cancer Center, joins Amalya Sargsyan to discuss the IGNYTE-ESO trial. This pioneering study highlights Lete-cel, an adoptive T-cell therapy showing a 42% response rate in synovial sarcoma and myxoid round cell liposarcoma (MRCLS). Dr. D'Angelo delves into key findings, including response durability, safety profiles, and the transformative potential of cell therapies in sarcoma care. Tune in for expert insights into the future of sarcoma treatment! ‪@mskcc‬ #Cancer #Oncology #OncoDaily #SarcomaTreatment #MSKCC #LeteCel #CellTherapy #MRCLS #SynovialSarcoma #CancerResearch #AdoptiveTCellTherapy #SarcomaCare #CancerInnovation #FutureOfOncology #SarcomaExperts 00:00 Introduction 01:11 IGNYTE-ESO Trial: Overview and Clinical Context 05:24 New Hope for Sarcoma Patients 08:23 Safety and Side Effects of Lete-cel 11:08 Exploring Cell Therapy and Lete-Cel 14:17 Future of Cell Therapies in Sarcomas: Promise and Progress SUBSCRIBE to get the latest #oncodaily    / @oncodailytv   Visit the OncoDaily Website : https://oncodaily.com Like OncoDaily on LinkedIn:   / oncodaily   Like OncoDaily on X (Twitter): https://x.com/oncodaily Follow OncoDaily on Instagram:   / oncodailynews   Follow OncoDaily on TikTok:   / oncodaily   Like OncoDaily on Facebook:   / oncodaily   SUBSCRIBE to OncoDaily Newsletter: https://oncodaily.com/submit-newsletter About OncoDaily OncoDaily is a world-leading oncology media platform, which is based in the United States and features the cancer related latest news, insights, and patient stories from around the globe. The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we.”